Results 201 to 210 of about 67,967 (294)

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Characterization of Bioactive Compounds in Spent Mushroom Substrate: A Metabolomic Perspective on Its Untapped Potential. [PDF]

Foods
Zhang L, Cheah IK, Lu Y, Huang D, Loo AEK.   +4 more
europepmc   +1 more source

Case of Food Ileus Where It Was Difficult to Rule Out Indigitation of Small Bowel Tumor Following Swallowing a Mushroom

, 2019
Masatsugu Ishii, Shoko OOSUGI
openalex   +2 more sources

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

A Conjoint Analysis of Consumer Preferences on Shiitake Mushrooms: A Case Study of the Republic of Korea. [PDF]

Foods
Lee C, Kim K.
europepmc   +1 more source

LC–MS/MS based-comparative study of (S)-nicotine metabolism by microorganisms, mushroom and plant cultures: Parallels to its mammalian metabolic fate

, 2015
Amira R. Khattab, Abdel‐Rahim S. Ibrahim, Souzan M. Ibrahim, Kamillia A. Abou El-Seoud, Wafaa E. Soliman, Fathy K. El-Fiky   +5 more
openalex   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Current Knowledge and Utilization of Medicinal Plants and Fungi in Northeastern Croatia. [PDF]

Plants (Basel)
Krstin L, Katanić Z, Turk I, Gajski I, Pfeiffer TŽ.   +4 more
europepmc   +1 more source

Mushroom and mushroom-vegetable pastes from wild edible mushrooms

Karstenia, 1978
Wanda Woźniak, Eugenia Sobkowska, Anna Kwiatkowska   +2 more
openaire   +1 more source